Quick Answer
Acumen Pharmaceuticals, Inc. reported Operating Income Loss of -$123.83 million for the year ending 2025.
- Acumen Pharmaceuticals, Inc. showed a decrease of -8.6% in Operating Income Loss from 2024 to 2025.
- This data is from Acumen Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Acumen Pharmaceuticals, Inc.'s Operating Income Loss has declined by 1,465.1%.
- Historical annual values: Fiscal year 2025: -$123.83 million | Fiscal year 2024: -$114.02 million | Fiscal year 2023: -$61.14 million | Fiscal year 2022: -$45.24 million | Fiscal year 2021: -$19.58 million | Fiscal year 2020: -$7.91 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: